USC Donations Drop $100 Million after Puliafito Scandal, Report Says

February 9, 2018: By Joan McKenna

The University of Southern California saw a $100 million drop in contributions in the last half of 2017 in the wake of a scandal involving former ophthalmologist Carmen Puliafito, according to a story published Feb. 7 by The Los Angeles Times.

Donations dropped $45 million, or 55 percent, within USC’s Keck School of Medicine, where Puliafito served as dean from August 2007 to March 2016.

The decline in support followed publication of a Los Angeles Times story in July 2017 alleging that Puliafito used methamphetamine and other drugs and kept company with prostitutes and drug users, sometimes on campus, while he was dean. In the aftermath, the university faced numerous related expenses as it hired crisis managers and launched an investigation into the school’s handling of the scandal.

University officials attributed the decline in contributions to normal fluctuations in fundraising.

Two USC employees involved with fundraising told the LA Times that donors were affected by the scandal and felt the school’s moral compass didn’t fit their own anymore.

USC has transformed its fundraising efforts in recent years. It launched a $6 billion fundraising campaign in 2011 and surpassed its goal in 6 1/2 years, raising as much in that time as it had in the previous 6 1/2 decades combined, the school said.

Puliafito’s own reputation was built around his fundraising prowess, both at USC and Bascom Palmer Eye Institute.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Carl Zeiss Meditec Announces Milestone of 1.5 Million SMILE Procedures

Heidelberg Gains US Clearance for OCT Angiography Module

ASCRS Convenes Task Force to Study CyPass Data, Make Recommendations

Bascom Palmer Treats First US Patient in Nightstar’s Trial for X-Linked Retinitis Pigmentosa

First Patient Treated in Allotex’ Trial for Allogenic Refractive Lenticules for Presbyopia

Bausch + Lomb Announces Positive Results for Loteprednol Etabonate Gel

LumiThera Set to Launch Valeda Light Delivery System for Dry AMD

Kodiak Sciences Names Jason Ehrlich, MD, PhD, Chief Medical Officer

Second Sight Receives $1.6 Million Grant from NIH to Support Orion Program

Regeneron to Invest $800 Million in New York Campus

American Women Raise Funds for Nepal Mission to Reduce Corneal Blindness

Ziemer to Add Lenticule Extraction Capabilities to LDV Z8

Stealth BioTherapeutics Raises $100 Million in Support of Elamipretide for Dry AMD

STAAR Gains US Approval of Visian Toric ICL

Sun Pharma, SPARC Announce FDA Approval for Xelpros for Open-Angle Glaucoma, Ocular Hypertension

FDA Will Review Regeneron’s Submission to Expand Eylea’s Labeling to All DR Patients

Alcon Will Locate Headquarters in Switzerland

Kodiak Sciences Files for $100 Million IPO

Iridex Announces $10 Million Public Offering

Oxford BioMedica Expands Capacity with New Facility